US2022315927A1PendingUtilityA1
Modulators of yap1 expression
Est. expiryJan 31, 2039(~12.5 yrs left)· nominal 20-yr term from priority
A61K 31/7088C12N 2310/346A61K 9/0012A61K 45/06C12N 2310/3231C12N 2320/31C12N 15/11A61P 35/00C12N 15/113C12N 2310/315A61K 31/7125C12N 15/1135A61K 31/712C12N 2320/11C12N 2310/321C12N 2310/341A61K 45/00A61K 31/44C12N 2310/11C12N 2310/3341
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present embodiments provide methods, compounds, and compositions useful for inhibiting YAP1 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with YAP1.
Claims
exact text as granted — not AI-modified1 .- 8 . (canceled)
9 . A compound comprising a modified oligonucleotide consisting of 8 to 80 linked nucleosides and having a nucleobase sequence comprising at least 8 contiguous nucleobases of a nucleobase sequence selected from the group consisting of SEQ ID NOs: 810, 1404, 2868, 2864, 286-5-1-494-1101, 2812, 1200, and 2863.
10 .- 16 . (canceled)
17 . A compound comprising a modified oligonucleotide having a nucleobase sequence consisting of a nucleobase sequence selected from the group consisting of SEQ ID NOs: 810, 1404, 2868, 2864, 286-1-404, 1101, 2812, 1200, or 2863.
18 . The compound of claim 17 , wherein at least one internucleoside linkage of the modified oligonucleotide is a modified internucleoside linkage, at least one sugar of the modified oligonucleotide is a modified sugar, or at least one nucleobase of the modified oligonucleotide is a modified nucleobase.
19 . The compound of claim 18 , wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.
20 . The compound of claim 18 , wherein the modified sugar is a bicyclic sugar.
21 . The compound of claim 20 , wherein the bicyclic sugar is selected from the group consisting of: 4′-(CH 2 )—O—2′ (LNA); 4′-(CH 2 ) 2 —O—2′ (ENA); and 4′-CH(CH 3 )—O—2′ (cEt).
22 . The compound of claim 18 , wherein the modified sugar is 2′-O-methoxyethyl.
23 . The compound of claim 18 , wherein the modified nucleobase is 5-methylcytosine.
24 . The compound of claim 17 , wherein the modified oligonucleotide has:
a gap segment consisting of linked 2′-deoxynucleosides; a 5′ wing segment consisting of linked nucleosides; and a 3′ wing segment consisting of linked nucleosides; wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.
25 .- 37 . (canceled)
38 . A compound consisting of a pharmaceutically acceptable salt of the compound of claim 17 .
39 . The compound of claim 38 , wherein the pharmaceutically acceptable salt is a sodium salt.
40 . The compound of claim 38 , wherein the pharmaceutically acceptable salt is a potassium salt.
41 . (canceled)
42 . (canceled)
43 . (canceled)
44 . A composition comprising the compound of claim 17 and a pharmaceutically acceptable diluent or carrier.
45 . A composition comprising the compound of claim 17 and water.
46 . (canceled)
47 . A combination comprising the compound of claim 17 and a secondary agent.
48 . The combination of claim 47 , wherein the secondary agent is a CDK4/6 inhibitor.
49 . (canceled)
50 . The combination of claim 47 , wherein the secondary agent is an EGFR inhibitor.
51 . (canceled)
52 . The combination of claim 47 , wherein the secondary agent is a kinase inhibitor.
53 .- 64 . (canceled)
65 . A method of inhibiting expression of YAP1 in a cell comprising contacting the cell with a compound of claim 17 , thereby inhibiting expression of YAP1 in the cell.
66 . The method of claim 65 , wherein the cell a cancer cell.
67 .- 99 . (canceled)Join the waitlist — get patent alerts
Track US2022315927A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.